Overview

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Status:
Terminated

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be eligible for PDT.

Phase:

Phase 4

Details

Lead Sponsor:

Eyetech Pharmaceuticals

Collaborator:

Pfizer

Treatments:

Verteporfin